These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2459538)

  • 1. Hemodynamic effects of a constant intravenous infusion of piroximone in patients with severe congestive heart failure.
    Miller WE; Kennedy GT; Ruberg SJ; O'Rourke RA; Crawford MH
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):72-7. PubMed ID: 2459538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure.
    Baumann PC; Meyer BJ; Maggiorini M; Ha HR; Gallino A; Follath F
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):489-95. PubMed ID: 7681513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure.
    Petein M; Levine TB; Cohn JN
    J Am Coll Cardiol; 1984 Aug; 4(2):364-71. PubMed ID: 6736478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.
    Albo C; Saal JP; Lellouche D; Habbal R; Benvenuti C; Deleuze P; Loisance D; Castaigne A; Dubois-Randé JL
    Eur Heart J; 1994 Apr; 15(4):528-33. PubMed ID: 8070481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure.
    Axelrod RJ; De Marco T; Dae M; Botvinick EH; Chatterjee K
    J Am Coll Cardiol; 1987 May; 9(5):1124-30. PubMed ID: 3571752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term therapy with oral piroximone on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure.
    Nemanich JW; Shurman AJ; Rossen JD; Kremser C; Davis F; Rajfer SI
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):580-8. PubMed ID: 2447409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
    Kereiakes D; Chatterjee K; Parmley WW; Atherton B; Curran D; Kereiakes A; Spangenberg R
    J Am Coll Cardiol; 1984 Nov; 4(5):884-9. PubMed ID: 6238076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside.
    Massie BM; Cornyn J; Topic N; Loge D; Podolin RA
    Am J Cardiol; 1987 Sep; 60(8):647-53. PubMed ID: 3661429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hemodynamic effects of piroximone (MDL 19,205) in patients with moderate congestive heart failure: comparison with sodium nitroprusside.
    Arbogast R; Brandt CM; Fincker JL; Schechter PJ
    J Cardiovasc Pharmacol; 1986; 8(1):82-9. PubMed ID: 2419699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure.
    Weber KT; Janicki JS; Jain MC
    Am Heart J; 1987 Oct; 114(4 Pt 1):805-13. PubMed ID: 3310566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    J Am Coll Cardiol; 1985 Jun; 5(6):1414-21. PubMed ID: 3158689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute hemodynamic effects of piroximone i.v. in patients with severe heart failure].
    Scholz M; Kneissl GD; Winkelmann BW; Grohe G; Klittich P; Bussmann WD
    Z Kardiol; 1995 Oct; 84(10):827-33. PubMed ID: 7502570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and regional blood flow response to piroximone (MDL 19,205) in dogs with congestive heart failure: a comparison with dobutamine.
    Petein M; Heppner B; Bache RJ; Cohn JN; Pierpont GL
    J Pharmacol Exp Ther; 1987 Jun; 241(3):956-60. PubMed ID: 3598911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.
    Khalife K; Zannad F; Brunotte F; Belhadj K; Juilliere Y; Iannascoli F; Gilgenkrantz JM
    Am J Cardiol; 1987 Aug; 60(5):75C-79C. PubMed ID: 2956874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.
    Rubin SA; Tabak L
    J Am Coll Cardiol; 1985 Jun; 5(6):1422-7. PubMed ID: 3158690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure.
    Amin DK; Shah PK; Hulse S; Shellock F
    Am Heart J; 1985 May; 109(5 Pt 1):1006-12. PubMed ID: 3158182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of prolonged intravenous therapy with enoximone in patients with severe congestive heart failure.
    Ferry DR; Kennedy GT; O'Rourke RA; Crawford MH
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):115-22. PubMed ID: 2450249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of piroximone on the right ventricular function in severe heart failure patients.
    Saal JP; Habbal R; Estagnasie P; Lellouche D; Castaigne A; Dubois-Randé JL
    Intensive Care Med; 1994 May; 20(5):341-7. PubMed ID: 7930028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.